<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01003158</url>
  </required_header>
  <id_info>
    <org_study_id>D0102C00010</org_study_id>
    <nct_id>NCT01003158</nct_id>
  </id_info>
  <brief_title>Study Assessing Safety and Tolerability of AZD8931 Alone or in Combination With Paclitaxel in Japanese Patients.</brief_title>
  <official_title>A Phase I, Open-label, Multiple-dose, Dose-escalation Study To Assess the Safety and Tolerability of AZD8931 Monotherapy in Japanese Patients With Advanced Solid Malignancies and in Combination With Paclitaxel in Japanese Female Patients With Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to determine if AZD8931 can be safely administered in
      Japanese patients alone and in combination with weekly paclitaxel. The study will be
      conducted in two parts: a monotherapy and a combination part, where safe doses of study
      treatment will be determined.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Monotherapy part: Assessment of adverse events, laboratory findings, physical examination, vital signs, ECG/UCG, chest X-ray, HRCT, SpO2 and ophthalmological examinations.</measure>
    <time_frame>Full routine safety assessment on days 1-4, 8, 10, 14, 21, 28 then every 3 weeks after first dose of study drug</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Combination part: The contents of same assessment as Monotherapy.</measure>
    <time_frame>Full routine safety assessment on days 1-5, 8, 15, 22, 28 then every 4 weeks after first dose of study drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Combination Part: Pharmacokinetics of AZD8931 (tmax, Cmax, AUC0-10)</measure>
    <time_frame>On Day D7 and Day D8: pre-dose then, 1, 2, 4, 6, 8 and 10 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combination Part: Pharmacokinetics of paclitaxel (tmax, Cmax, AUC0-10)</measure>
    <time_frame>On Days D1 and Day D8: pre-infusion then, 0.5, 1, 1.5, 2, 4, 6, 8, 10 and 24 (D1 only) hours post start of infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monotherapy Part: Pharmacokinetics of AZD8931 (Single dose plasma PK: AUC0-10, AUC0-12, AUC0-24, AUC0-t, AUC, Cmax, tmax, t1/2, CL/F, Vss/F. Multiple dose plasma PK: AUCss0-10, AUCss0-12, Cssmax, tssmax, Cssmin, CLss/F, RAC, linearity factor)</measure>
    <time_frame>On single dose Day 1 (D1) and multiple dose Day 21 (R14): samples taken pre-dose then 1, 2, 4, 6, 8, 10, 24 (D1 only), 48 (D1 only) and 72 (D1 only) hours post dose. Day 10 (R3) and Day 14 (R7): pre-dose only</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Neoplasms</condition>
  <condition>Metastatic Cancer</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Monotherapy part</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD8931 monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination part</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD8931 plus paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD8931</intervention_name>
    <description>Tablet Oral bid</description>
    <arm_group_label>Monotherapy part</arm_group_label>
    <arm_group_label>Combination part</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>IV once weekly for 3 weeks followed by a week off</description>
    <arm_group_label>Combination part</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cancer that is refractory to standard therapies, or for which no standard therapies
             exist (monotherapy part)

          -  Patients suitable for Paclitaxel chemotherapy, who are not candidates for hormonal and
             anthracycline therapy (combination part)

          -  Life expectancy more than 12 weeks

        Exclusion Criteria:

          -  Inadequate kidney, liver, heart, gastric, lung or eye function

          -  Brain metastases

          -  Hypersensitive to paclitaxel (combination part)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Stuart, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Takayasu Kurata, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kinki University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=1627&amp;filename=D0102C00010_Clinical_Study_Protocol_combined_redacted_v02a.pdf</url>
    <description>Reducted Protocol</description>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=1627&amp;filename=AZD8931_Clinical_Study_Protocol_Redacted.pdf</url>
    <description>Clinical Study Protocol Redacted</description>
  </link>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2009</study_first_submitted>
  <study_first_submitted_qc>October 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2009</study_first_posted>
  <last_update_submitted>July 9, 2014</last_update_submitted>
  <last_update_submitted_qc>July 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>tumour</keyword>
  <keyword>metastatic</keyword>
  <keyword>breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

